Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Rhea-AI Summary

Palisade Bio (Nasdaq:PALI) announced that President and Chief Medical Officer Mitchell Jones, MD, PhD, will present at the New York Academy of Sciences fibrosis symposium on June 9, 2026.

The talk will cover fibrostenotic Crohn’s disease, intestinal fibrosis biology, and the potential of PALI-2108, a locally bioactivated PDE4 inhibitor prodrug.

News Market Reaction – PALI

-2.87%

-2.87% Session close to close

In the Jun 9 session, PALI declined 2.87%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Palisade Bio’s effort to position PALI-2108 within the fibrosis and fib...

Analysis

This announcement highlights Palisade Bio’s effort to position PALI-2108 within the fibrosis and fibrostenotic Crohn’s disease landscape, emphasizing a locally bioactivated PDE4 inhibitor prodrug approach and preclinical findings. Recent history shows multiple scientific and investor presentations with mixed short-term price impact. Investors may focus on how this FSCD-focused narrative complements prior Phase 1a/1b data, the timing of planned Phase 2 trials, and the financing flexibility provided by the $300,000,000 shelf registration.

Key Figures

Shelf registration size: $300,000,000 Phase 1/1b subjects: 89 subjects FSCD patients: 5 patients +5 more

8 metrics

Shelf registration size $300,000,000 S-3 shelf filed 2026-05-12 for various securities

Phase 1/1b subjects 89 subjects Completed Phase 1/1b programs for PALI-2108 (healthy + UC cohorts)

FSCD patients 5 patients Exploratory fibrostenotic Crohn’s disease cohort in PALI-2108 program

Soleus ownership 9,353,687 shares (5.4%) Schedule 13G based on 173,579,670 shares outstanding as of May 7, 2026

RA Capital ownership 17,620,479 shares (9.99%) Schedule 13G/A with pre-funded warrant blocker as of Mar 31, 2026

Perceptive ownership 14,113,863 shares (7.9%) Schedule 13G/A based on 173,579,670 shares outstanding as of May 7, 2026

Ameriprise ownership 8,711,385 shares (5.3%) Schedule 13G institutional holding disclosure

Cash balance $132.6 million Cash, cash equivalents and restricted cash as of Mar 31, 2026 (10-Q)

Historical Context

5 past events · Latest: May 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	Investor conference	Positive	+4.0%	Jefferies Global Healthcare Conference presentation and investor meetings in New York.
May 12	Earnings and pipeline	Positive	-2.6%	Q1 2026 results and Phase 2 planning for PALI-2108 in UC and CD.
May 05	Clinical data update	Positive	-7.5%	Additional Phase 1a/b data showing colon-targeted exposure and IC90 coverage in UC.
Apr 16	Conference poster	Positive	-0.4%	DDW 2026 poster selection for translational Phase 1 data on PALI-2108.
Apr 08	Investor conference	Positive	-2.1%	Needham 25th Annual Healthcare Conference presentation and 1x1 investor meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows frequent sell-offs or muted action following generally positive clinical and investor-relations news, with only one clearly positive price reaction.

Recent Company History

Over the past few months, Palisade Bio has consistently highlighted progress for PALI-2108. Multiple conference and meeting presentations (Needham, DDW 2026, Jefferies) and positive Phase 1a/1b data emphasized colon-targeted exposure and once-daily dosing potential. Q1 2026 results showed a wider loss but $132.6M in cash to fund Phase 2 trials. Despite constructive updates, four of the last five announcements led to negative or flat next-day moves, underscoring a cautious market stance toward good news.

Key Terms

pde4 inhibitor, prodrug, fibrostenotic crohn’s disease, intestinal fibrosis, +4 more

8 terms

pde4 inhibitor medical

"next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery"

A PDE4 inhibitor is a drug that blocks an enzyme (PDE4) involved in turning off certain cell signals linked to inflammation and brain activity; blocking it lets those signals persist and can reduce inflammation or alter nerve-cell behavior. Investors care because this drug class underlies treatments for conditions like chronic inflammatory and neurological disorders, so clinical trial results, regulatory decisions, or patent news can strongly affect a company’s drug pipeline value and stock outlook.

prodrug medical

"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"

A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it's ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug's regulatory path, marketability, and commercial value.

fibrostenotic crohn’s disease medical

"Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn’s Disease"

Fibrostenotic Crohn’s disease is a form of inflammatory bowel disease where repeated inflammation leads to scar tissue that narrows sections of the intestine, causing pain, partial or full blockages and the need for repeated procedures. For investors, it matters because this predictable, chronic narrowing creates a clear medical need for drugs, devices and procedures, shaping market size, development priorities, clinical trial design and potential long‑term healthcare costs—like a plumbing pipe repeatedly clogged by hardened deposits.

intestinal fibrosis medical

"the biological mechanisms underlying intestinal fibrosis and the potential role"

Intestinal fibrosis is the buildup of scar-like tissue in the walls of the intestines that makes them stiff, narrow and less able to move food—like a garden hose that becomes hard and squeezed. For investors, it matters because fibrosis drives chronic symptoms, surgeries and long-term care needs, creating demand for drugs, diagnostics and medical devices while affecting regulatory approval prospects, treatment costs and the market potential for new therapies.

pde4 inhibition medical

"the potential role of locally bioactivated PDE4 inhibition as a novel therapeutic approach"

PDE4 inhibition is blocking the activity of the enzyme phosphodiesterase-4, which normally helps turn off certain cellular signals. Like releasing a handbrake so a car can cruise more smoothly, inhibiting PDE4 amplifies internal signaling that can reduce inflammation and change cell behavior. For investors, it describes a drug’s mechanism of action that can drive clinical benefit, regulatory decisions and market potential in conditions where inflammation or immune activity is central.

preclinical medical

"discuss preclinical findings supporting PDE4 inhibition as a potential strategy"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

multiomic medical

"to explore advances in fibrosis biology, emerging multiomic insights and the development"

Multiomic describes the combined analysis of different layers of biological information—such as genes, proteins and small molecules—to build a more complete picture of how cells and diseases work. Like viewing a problem from several camera angles instead of one, it can reveal stronger drug targets, clearer diagnostic markers and better predictions of who will benefit from a therapy, which helps investors assess scientific validity, market potential and development risk.

organ fibrosis medical

"Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis"

Organ fibrosis is the build-up of stiff, scar-like tissue inside organs (like the liver, lungs, or heart) after repeated injury or inflammation, which reduces their ability to work — think of healthy tissue being replaced by a stiff patch that can’t stretch or filter properly. It matters to investors because fibrosis drives chronic disease, creates large markets for drugs and diagnostics, influences the success and timeline of clinical trials, and affects long-term healthcare costs and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach

Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences (“NYAS”) symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026, in New York, NY.

The symposium brings together leading experts from academia, industry and clinical research to explore advances in fibrosis biology, emerging multiomic insights and the development of novel therapeutic approaches across a range of fibrotic diseases.

Dr. Jones’ presentation, titled “Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn’s Disease (FSCD),” will discuss the significant unmet need associated with FSCD, the biological mechanisms underlying intestinal fibrosis and the potential role of locally bioactivated PDE4 inhibition as a novel therapeutic approach.

“Fibrosis remains one of the most significant challenges facing patients with Crohn’s disease, yet there are currently no approved therapies specifically designed to address FSCD,” said Mitchell Jones, MD, PhD, President and Chief Medical Officer of Palisade Bio. “We are honored to participate in this important scientific meeting and look forward to contributing to the broader discussion surrounding fibrosis biology and emerging therapeutic strategies.”

The presentation will also highlight the scientific rationale supporting PALI-2108, Palisade’s locally bioactivated PDE4 inhibitor prodrug. In addition, Dr. Jones will discuss preclinical findings supporting PDE4 inhibition as a potential strategy for modulating key inflammatory and fibrotic pathways implicated in FSCD.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and FSCD.

Palisade is now advancing towards Phase 2 clinical studies in UC and Crohn’s disease. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: the potential mechanisms of action and therapeutic benefits of PALI-2108 for the treatment of FSCD and UC and plans for and timing of regulatory submissions and approvals, clinical trials and efficacy readouts. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

What is Palisade Bio (PALI) presenting at the New York Academy of Sciences symposium on June 9, 2026?

Palisade Bio is presenting on a locally bioactivated PDE4 inhibitor prodrug approach for fibrostenotic Crohn’s disease. According to Palisade Bio, Mitchell Jones will discuss intestinal fibrosis biology, unmet needs in FSCD, and the therapeutic potential of targeted PDE4 inhibition.

What is PALI-2108 and how is it linked to fibrostenotic Crohn’s disease (FSCD)?

PALI-2108 is described as a locally bioactivated PDE4 inhibitor prodrug targeting the terminal ileum and colon. According to Palisade Bio, the presentation will outline the scientific rationale for PALI-2108 as a potential novel approach for inflammatory and fibrotic pathways in FSCD.

Why does Palisade Bio see fibrostenotic Crohn’s disease as a major unmet medical need?

Palisade Bio highlights fibrosis in Crohn’s disease as a major challenge, with no therapies specifically approved for FSCD. According to Palisade Bio, this unmet need motivates exploration of locally bioactivated PDE4 inhibition to address fibrotic and inflammatory mechanisms in affected intestinal tissue.

Who from Palisade Bio (PALI) is speaking at the New York Academy of Sciences fibrosis symposium?

Mitchell Jones, MD, PhD, President and Chief Medical Officer of Palisade Bio, is the presenter. According to Palisade Bio, he will speak at the Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis symposium in New York on June 9, 2026.

What scientific topics will Palisade Bio cover about PALI-2108 at the NYAS fibrosis symposium?

The presentation will review intestinal fibrosis biology, FSCD’s unmet need, and PDE4 inhibition as a therapeutic concept. According to Palisade Bio, it will also highlight the scientific rationale and preclinical findings supporting PALI-2108’s potential to modulate key inflammatory and fibrotic pathways.

How does Palisade Bio describe the role of PDE4 inhibition in treating fibrostenotic Crohn’s disease?

Palisade Bio describes PDE4 inhibition as a potential strategy to affect inflammatory and fibrotic pathways in FSCD. According to Palisade Bio, preclinical findings suggest locally bioactivated PDE4 inhibitor prodrugs could help target disease processes in the terminal ileum and colon.